MiMedx Group (MDXG) – Research Analysts’ Weekly Ratings Updates

MiMedx Group (NASDAQ: MDXG) has recently received a number of price target changes and ratings updates:

• 5/4/2026 – MiMedx Group was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 5/2/2026 – MiMedx Group was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/30/2026 – MiMedx Group had its price target lowered by Citizens Jmp from $7.00 to $6.00. They now have a “market outperform” rating on the stock.
• 4/20/2026 – MiMedx Group had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $7.00 price target on the stock, down from $10.00.
• 4/17/2026 – MiMedx Group had its price target lowered by Craig Hallum from $10.00 to $7.00. They now have a “buy” rating on the stock.

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.